Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant <i>Acinetobacter baumannii</i> Infections-A Meta-Analysis

• Main Authors: Chienhsiu Huang (Author), Lichen Lin (Author), Sufang Kuo (Author)
• Format: Book
• Published: MDPI AG, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/antibiotics13090907; 2079-6382
• Keywords: <i>Acinetobacter baumannii</i>; cefoperazone; sulbactam; mortality; multiresistant; Therapeutics. Pharmacology; RM1-950
• Source: Antibiotics, Vol 13, Iss 9, p 907 (2024)

The addition of sulbactam restores the complete range of cefoperazone activity against bacteria and extends its spectrum of action to include the <i>Acinetobacter</i> species. The effectiveness of cefoperazone/sulbactam against multiresistant <i>Acinetobacter baumannii</i> has not been investigated. The purpose of the current meta-analysis was to compare the efficacy of cefoperazone/sulbactam-based therapeutic regimens and non-cefoperazone/sulbactam-based therapeutic regimens in the treatment of multiresistant <i>Acinetobacter baumannii</i> infections. The current meta-analysis of 10 retrospective studies provides evidence that cefoperazone/sulbactam-based therapeutic regimens are superior to non-cefoperazone/sulbactam-based therapeutic regimens in terms of 30-day mortality and clinical improvement in patients with multiresistant <i>Acinetobacter baumannii</i> infections. The risk of mortality was reduced by 38% among multiresistant <i>Acinetobacter baumannii</i> infections in patients who received cefoperazone/sulbactam-based therapeutic regimens. The cefoperazone/sulbactam-based combination therapy was superior to the cefoperazone/sulbactam monotherapy in terms of 30-day mortality when both therapeutic regimens were compared to the tigecycline monotherapy in patients with multiresistant <i>Acinetobacter baumannii</i> infections.